Search

Editorial Feature:

AMD/DME Case Files: Real-World Patient Profiles

Editorially Independent content supported with advertising by Genentech

Switch Case: 66-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Show Description +

Does switching from aflibercept 2 mg (Eylea, Regeneron) to faricimab (Vabysmo, Genentech/Roche) in a wet AMD patient with slight recurrent fluid allow extended treatment intervals? Priya Sharma Vakharia, MD, shares a real-world case from her clinic, which sparks a discussion about dosing strategies when switching to a new agent.

Posted: 1/15/2024

Keywords:

aflibercept

•

wet amd

•

dosing strategies

•

recurrent fluid

•

Season Two

Up Next

Potential Switch Case: 81-Year-Old Man With Wet AMD

Potential Switch Case: 81-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Switch Case: Massive PED (Part 1)

Switch Case: Massive PED (Part 1)

Yasha S. Modi, MD

Switch Case: Massive PED (Part 2)

Switch Case: Massive PED (Part 2)

Yasha S. Modi, MD

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Joseph M. Coney, MD

Treatment-Naïve Case: DME in a 54-Year-Old-Patient With Undiagnosed Diabetes

Treatment-Naïve Case: DME in a 54-Year-Old-Patient With Undiagnosed Diabetes

Joseph M. Coney, MD

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

Real-World Step Therapy Case: A Challenging DME Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Difficult-to-Treat Fluid DME Case Study

Real-World Switch Case: Difficult-to-Treat Fluid DME Case Study

Ferhina Ali, MD

Real-World Step Therapy: Suboptimal Response in Wet AMD

Real-World Step Therapy: Suboptimal Response in Wet AMD

Scott Walter, MD, MSc

Real-World Treatment-Naïve Case: Bilateral Advanced DME Treated with Two Different Agents

Real-World Treatment-Naïve Case: Bilateral Advanced DME Treated with Two Different Agents

Scott Walter, MD, MSc

Switch Case: Potential Response to Ang-2 in Wet AMD

Switch Case: Potential Response to Ang-2 in Wet AMD

Ash Abbey, MD

Switch Case: Faricimab to High-dose Aflibercept

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Back to All Videos

Switch Case: 66-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Does switching from aflibercept 2 mg (Eylea, Regeneron) to faricimab (Vabysmo, Genentech/Roche) in a wet AMD patient with slight recurrent fluid allow extended treatment intervals? Priya Sharma Vakharia, MD, shares a real-world case from her clinic, which sparks a discussion about dosing strategies when switching to a new agent.

Posted: 1/15/2024

Keywords:

aflibercept

•

wet amd

•

dosing strategies

•

recurrent fluid

•

Season Two

Please log in to leave a comment.